Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12-03

AUTHORS

Takayoshi Tachibana, Satoshi Koyama, Taiki Andou, Yasufumi Ishiyama, Masatsugu Tanaka, Hideaki Nakajima, Heiwa Kanamori

ABSTRACT

A single-center retrospective study was performed with consecutive patients who received salvage therapy using ponatinib for the aim of allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018. A total of ten patients—seven with Ph-acute lymphoblastic leukemia (ALL) and three with chronic phase (CP)/accelerated phase chronic myeloid leukemia (CML)—were eligible. Eight patients had a history of a single tyrosine kinase inhibitor (TKI) use prior to ponatinib. Any mutation of the tyrosine kinase domain was detected in eight patients, including seven of T315I. The median dose of ponatinib was 15 mg with a median duration of 7 weeks (range 4–23 weeks). The median duration from the start of ponatinib to HCT was 54 days (range 35–175 days). Hematological remission was obtained in five Ph-ALL patients. Maintenance therapy of ponatinib was applied to five patients. No vascular occlusion event has occurred over this series of treatments. Salvage therapy with low-dose ponatinib appears to be safe and effective in patients with relapsed or refractory Ph-leukemia, which may immediately bridge to HCT. More... »

PAGES

162-168

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0

DOI

http://dx.doi.org/10.1007/s12185-018-02571-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110344846

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30511314


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Allografts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Induction Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maintenance Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Philadelphia Chromosome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tachibana", 
        "givenName": "Takayoshi", 
        "id": "sg:person.01074653417.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koyama", 
        "givenName": "Satoshi", 
        "id": "sg:person.01247710606.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247710606.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andou", 
        "givenName": "Taiki", 
        "id": "sg:person.07656342421.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07656342421.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishiyama", 
        "givenName": "Yasufumi", 
        "id": "sg:person.01362612150.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Masatsugu", 
        "id": "sg:person.01171141246.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakajima", 
        "givenName": "Hideaki", 
        "id": "sg:person.010061552415.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanamori", 
        "givenName": "Heiwa", 
        "id": "sg:person.01060176576.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40261-018-0623-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100557119", 
          "https://doi.org/10.1007/s40261-018-0623-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2015.217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013878219", 
          "https://doi.org/10.1038/bmt.2015.217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-017-2238-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085069121", 
          "https://doi.org/10.1007/s12185-017-2238-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12-03", 
    "datePublishedReg": "2018-12-03", 
    "description": "A single-center retrospective study was performed with consecutive patients who received salvage therapy using ponatinib for the aim of allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018. A total of ten patients\u2014seven with Ph-acute lymphoblastic leukemia (ALL) and three with chronic phase (CP)/accelerated phase chronic myeloid leukemia (CML)\u2014were eligible. Eight patients had a history of a single tyrosine kinase inhibitor (TKI) use prior to ponatinib. Any mutation of the tyrosine kinase domain was detected in eight patients, including seven of T315I. The median dose of ponatinib was 15\u00a0mg with a median duration of 7\u00a0weeks (range 4\u201323\u00a0weeks). The median duration from the start of ponatinib to HCT was 54\u00a0days (range 35\u2013175\u00a0days). Hematological remission was obtained in five Ph-ALL patients. Maintenance therapy of ponatinib was applied to five patients. No vascular occlusion event has occurred over this series of treatments. Salvage therapy with low-dose ponatinib appears to be safe and effective in patients with relapsed or refractory Ph-leukemia, which may immediately bridge to HCT.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-018-02571-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6835407", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "109"
      }
    ], 
    "keywords": [
      "hematopoietic cell transplantation", 
      "tyrosine kinase inhibitors", 
      "Ph-leukemia", 
      "median duration", 
      "chronic phase", 
      "cell transplantation", 
      "refractory Philadelphia chromosome-positive leukemias", 
      "single-center retrospective study", 
      "allogeneic hematopoietic cell transplantation", 
      "phase chronic myeloid leukemia", 
      "Philadelphia chromosome-positive leukemia", 
      "chronic myeloid leukemia", 
      "patients seven", 
      "salvage therapy", 
      "maintenance therapy", 
      "median dose", 
      "hematological remission", 
      "consecutive patients", 
      "retrospective study", 
      "lymphoblastic leukemia", 
      "myeloid leukemia", 
      "patients", 
      "ponatinib", 
      "therapy", 
      "tyrosine kinase domain", 
      "kinase inhibitors", 
      "leukemia", 
      "series of treatments", 
      "transplantation", 
      "duration", 
      "remission", 
      "T315I.", 
      "salvage", 
      "dose", 
      "weeks", 
      "treatment", 
      "total", 
      "inhibitors", 
      "kinase domain", 
      "occlusion events", 
      "days", 
      "aim", 
      "mutations", 
      "history", 
      "study", 
      "start", 
      "events", 
      "series", 
      "phase", 
      "pH", 
      "domain"
    ], 
    "name": "Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia", 
    "pagination": "162-168", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110344846"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-018-02571-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30511314"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-018-02571-0", 
      "https://app.dimensions.ai/details/publication/pub.1110344846"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_775.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-018-02571-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-018-02571-0'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      22 PREDICATES      98 URIs      87 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-018-02571-0 schema:about N206a390cbfb94343bde6e82b7a77a782
2 N31b6299dba474d4aa9ab1c7b3afb92c4
3 N365197dafc7c4d689f368030ec5d60cb
4 N5ed8eaad201749c0a0cd81be5f8a58f8
5 N65c8ed9d161443d891b58206baa26bbd
6 N92c2b30cb5fd450eb7129dd7c9d34f22
7 N979c9e8e1c8b4467a35ea88041bcfaff
8 N9bab939aa3374e92a5fd267a95d65214
9 Na0d1e617ffbc4558965cd94ed61286fd
10 Nbc5e70ffc9ea424cb4987577e513c8f8
11 Nc6b2dd04d8e4489384633e4aad0c6465
12 Ncbb8ebc384614556865dc28e8f00efd1
13 Nd5cdcf8b8917444d8577aeeb1d98c111
14 Ne2f4fb5f44fa4d63808741cf34ef2698
15 Ne31b94939458467dbe8a5d7d360a3d1d
16 Nf36f2ff599da4e59a4489a1d20666ec6
17 Nfa048bc48dd5495d96b2342eadf9957f
18 Nfe46130d57024d608d49b275403b4a4f
19 anzsrc-for:11
20 anzsrc-for:1102
21 schema:author N009cb77e1f6246359e96512690ddd8d8
22 schema:citation sg:pub.10.1007/s12185-017-2238-9
23 sg:pub.10.1007/s40261-018-0623-7
24 sg:pub.10.1038/bmt.2015.217
25 schema:datePublished 2018-12-03
26 schema:datePublishedReg 2018-12-03
27 schema:description A single-center retrospective study was performed with consecutive patients who received salvage therapy using ponatinib for the aim of allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018. A total of ten patients—seven with Ph-acute lymphoblastic leukemia (ALL) and three with chronic phase (CP)/accelerated phase chronic myeloid leukemia (CML)—were eligible. Eight patients had a history of a single tyrosine kinase inhibitor (TKI) use prior to ponatinib. Any mutation of the tyrosine kinase domain was detected in eight patients, including seven of T315I. The median dose of ponatinib was 15 mg with a median duration of 7 weeks (range 4–23 weeks). The median duration from the start of ponatinib to HCT was 54 days (range 35–175 days). Hematological remission was obtained in five Ph-ALL patients. Maintenance therapy of ponatinib was applied to five patients. No vascular occlusion event has occurred over this series of treatments. Salvage therapy with low-dose ponatinib appears to be safe and effective in patients with relapsed or refractory Ph-leukemia, which may immediately bridge to HCT.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N2e92634438354e70bc8f1296c668acca
32 Nfdec7c47d10046a9be39a7f22f976ea4
33 sg:journal.1076985
34 schema:keywords Ph-leukemia
35 Philadelphia chromosome-positive leukemia
36 T315I.
37 aim
38 allogeneic hematopoietic cell transplantation
39 cell transplantation
40 chronic myeloid leukemia
41 chronic phase
42 consecutive patients
43 days
44 domain
45 dose
46 duration
47 events
48 hematological remission
49 hematopoietic cell transplantation
50 history
51 inhibitors
52 kinase domain
53 kinase inhibitors
54 leukemia
55 lymphoblastic leukemia
56 maintenance therapy
57 median dose
58 median duration
59 mutations
60 myeloid leukemia
61 occlusion events
62 pH
63 patients
64 patients seven
65 phase
66 phase chronic myeloid leukemia
67 ponatinib
68 refractory Philadelphia chromosome-positive leukemias
69 remission
70 retrospective study
71 salvage
72 salvage therapy
73 series
74 series of treatments
75 single-center retrospective study
76 start
77 study
78 therapy
79 total
80 transplantation
81 treatment
82 tyrosine kinase domain
83 tyrosine kinase inhibitors
84 weeks
85 schema:name Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia
86 schema:pagination 162-168
87 schema:productId N138d0da93be3450b827d71fac51683af
88 N751048e161904ab29fb875ad6f058cf5
89 Na7b9018d5bc6450290cf49e05ad57172
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110344846
91 https://doi.org/10.1007/s12185-018-02571-0
92 schema:sdDatePublished 2022-05-20T07:35
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher Nd4600b67e85642d195f07137f0e3fa96
95 schema:url https://doi.org/10.1007/s12185-018-02571-0
96 sgo:license sg:explorer/license/
97 sgo:sdDataset articles
98 rdf:type schema:ScholarlyArticle
99 N009cb77e1f6246359e96512690ddd8d8 rdf:first sg:person.01074653417.74
100 rdf:rest Ncc6ac5e09917409b9eb37c45cbf290d8
101 N138d0da93be3450b827d71fac51683af schema:name dimensions_id
102 schema:value pub.1110344846
103 rdf:type schema:PropertyValue
104 N206a390cbfb94343bde6e82b7a77a782 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N2af9d0bd84df476993ca41049e9beef3 rdf:first sg:person.01171141246.33
108 rdf:rest Nd4e25d592120446693e936246a604d50
109 N2e92634438354e70bc8f1296c668acca schema:issueNumber 2
110 rdf:type schema:PublicationIssue
111 N31b6299dba474d4aa9ab1c7b3afb92c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Allografts
113 rdf:type schema:DefinedTerm
114 N365197dafc7c4d689f368030ec5d60cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Pyridazines
116 rdf:type schema:DefinedTerm
117 N37dd0ec6412a4ce3838689fba2da843c rdf:first sg:person.01060176576.11
118 rdf:rest rdf:nil
119 N5ed8eaad201749c0a0cd81be5f8a58f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Middle Aged
121 rdf:type schema:DefinedTerm
122 N65c8ed9d161443d891b58206baa26bbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 N751048e161904ab29fb875ad6f058cf5 schema:name pubmed_id
126 schema:value 30511314
127 rdf:type schema:PropertyValue
128 N92c2b30cb5fd450eb7129dd7c9d34f22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Male
130 rdf:type schema:DefinedTerm
131 N979c9e8e1c8b4467a35ea88041bcfaff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Imidazoles
133 rdf:type schema:DefinedTerm
134 N9bab939aa3374e92a5fd267a95d65214 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Protein Kinase Inhibitors
136 rdf:type schema:DefinedTerm
137 Na0d1e617ffbc4558965cd94ed61286fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Salvage Therapy
139 rdf:type schema:DefinedTerm
140 Na7b9018d5bc6450290cf49e05ad57172 schema:name doi
141 schema:value 10.1007/s12185-018-02571-0
142 rdf:type schema:PropertyValue
143 Nb84ba55e34c04ef8ad36ce0f19dfc9fe rdf:first sg:person.01362612150.73
144 rdf:rest N2af9d0bd84df476993ca41049e9beef3
145 Nbc5e70ffc9ea424cb4987577e513c8f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adult
147 rdf:type schema:DefinedTerm
148 Nc6b2dd04d8e4489384633e4aad0c6465 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
150 rdf:type schema:DefinedTerm
151 Ncbb8ebc384614556865dc28e8f00efd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Hematopoietic Stem Cell Transplantation
153 rdf:type schema:DefinedTerm
154 Ncc6ac5e09917409b9eb37c45cbf290d8 rdf:first sg:person.01247710606.12
155 rdf:rest Nf5114270426e422d95efec56e74c43a2
156 Nd4600b67e85642d195f07137f0e3fa96 schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 Nd4e25d592120446693e936246a604d50 rdf:first sg:person.010061552415.35
159 rdf:rest N37dd0ec6412a4ce3838689fba2da843c
160 Nd5cdcf8b8917444d8577aeeb1d98c111 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Humans
162 rdf:type schema:DefinedTerm
163 Ne2f4fb5f44fa4d63808741cf34ef2698 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Induction Chemotherapy
165 rdf:type schema:DefinedTerm
166 Ne31b94939458467dbe8a5d7d360a3d1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Philadelphia Chromosome
168 rdf:type schema:DefinedTerm
169 Nf36f2ff599da4e59a4489a1d20666ec6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Maintenance Chemotherapy
171 rdf:type schema:DefinedTerm
172 Nf5114270426e422d95efec56e74c43a2 rdf:first sg:person.07656342421.67
173 rdf:rest Nb84ba55e34c04ef8ad36ce0f19dfc9fe
174 Nfa048bc48dd5495d96b2342eadf9957f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Retrospective Studies
176 rdf:type schema:DefinedTerm
177 Nfdec7c47d10046a9be39a7f22f976ea4 schema:volumeNumber 109
178 rdf:type schema:PublicationVolume
179 Nfe46130d57024d608d49b275403b4a4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Treatment Outcome
181 rdf:type schema:DefinedTerm
182 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
183 schema:name Medical and Health Sciences
184 rdf:type schema:DefinedTerm
185 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
186 schema:name Cardiorespiratory Medicine and Haematology
187 rdf:type schema:DefinedTerm
188 sg:grant.6835407 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-018-02571-0
189 rdf:type schema:MonetaryGrant
190 sg:journal.1076985 schema:issn 0925-5710
191 1865-3774
192 schema:name International Journal of Hematology
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.010061552415.35 schema:affiliation grid-institutes:grid.268441.d
196 schema:familyName Nakajima
197 schema:givenName Hideaki
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010061552415.35
199 rdf:type schema:Person
200 sg:person.01060176576.11 schema:affiliation grid-institutes:grid.414944.8
201 schema:familyName Kanamori
202 schema:givenName Heiwa
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11
204 rdf:type schema:Person
205 sg:person.01074653417.74 schema:affiliation grid-institutes:grid.414944.8
206 schema:familyName Tachibana
207 schema:givenName Takayoshi
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074653417.74
209 rdf:type schema:Person
210 sg:person.01171141246.33 schema:affiliation grid-institutes:grid.414944.8
211 schema:familyName Tanaka
212 schema:givenName Masatsugu
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171141246.33
214 rdf:type schema:Person
215 sg:person.01247710606.12 schema:affiliation grid-institutes:grid.414944.8
216 schema:familyName Koyama
217 schema:givenName Satoshi
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247710606.12
219 rdf:type schema:Person
220 sg:person.01362612150.73 schema:affiliation grid-institutes:grid.414944.8
221 schema:familyName Ishiyama
222 schema:givenName Yasufumi
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362612150.73
224 rdf:type schema:Person
225 sg:person.07656342421.67 schema:affiliation grid-institutes:grid.414944.8
226 schema:familyName Andou
227 schema:givenName Taiki
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07656342421.67
229 rdf:type schema:Person
230 sg:pub.10.1007/s12185-017-2238-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085069121
231 https://doi.org/10.1007/s12185-017-2238-9
232 rdf:type schema:CreativeWork
233 sg:pub.10.1007/s40261-018-0623-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100557119
234 https://doi.org/10.1007/s40261-018-0623-7
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/bmt.2015.217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013878219
237 https://doi.org/10.1038/bmt.2015.217
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.268441.d schema:alternateName Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
240 schema:name Department of Hematology and Clinical Immunology, School of Medicine, Yokohama City University, Yokohama, Japan
241 rdf:type schema:Organization
242 grid-institutes:grid.414944.8 schema:alternateName Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan
243 schema:name Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, 241-8515, Yokohama, Japan
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...